Zogenix shares down 23% after FDA refuses to review company’s marketing application for seizure drug

Shares of Zogenix, Inc. plunged 23% Tuesday after the company disclosed Monday evening that the Food and Drug Administration had refused to review the marketing application for a treatment of seizures associated with a rare form of childhood epilepsy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.